human retinal progenitor cells
Cell therapyexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02320812)
Timeline
Indications
Mechanism of action
- Unspecified targetTissue restoration
Tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- human retinal progenitor cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06912633 | Phase 2 | Jun 20, 2025 | jCyte, Inc |
| NCT05187104 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2022 | Belarusian State Medical University, National Academy of Sciences of Belarus |
| NCT04604899 | Phase 2 | Nov 30, 2020 | California Institute for Regenerative Medicine (CIRM), jCyte, Inc, Ophthalmic Consultants of Boston, Retina-Vitreous Associates Medical Group, University of California, Irvine |
| NCT03073733 | Phase 2 | Mar 1, 2017 | jCyte, Inc |
| NCT02320812 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2015 | jCyte, Inc |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| jCyte, Inc | For profit | 4 | 4 | 1 | 2015 |
| Belarusian State Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| National Academy of Sciences of Belarus | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Ophthalmic Consultants of Boston | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Retina-Vitreous Associates Medical Group | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1